The importance of confirmatory assays in testing blood donors for human T-cell lymphotropic virus.
HTLV-1/2
blood donor
confirmatory testing
screening
serology
Journal
Vox sanguinis
ISSN: 1423-0410
Titre abrégé: Vox Sang
Pays: England
ID NLM: 0413606
Informations de publication
Date de publication:
15 Jan 2024
15 Jan 2024
Historique:
revised:
30
11
2023
received:
09
10
2023
accepted:
04
12
2023
medline:
15
1
2024
pubmed:
15
1
2024
entrez:
15
1
2024
Statut:
aheadofprint
Résumé
Serological HTLV-1/2 screening is mandatory for blood donor candidates in Brazil. Our objective was to analyse HTLV test results in blood donors submitted for screening and confirmatory assays in a Brazilian blood bank. Retrospective analysis (2017-2022) results of chemiluminescence immunoassays and confirmatory tests for HTLV-1/2 in reactive donors were performed. During the analysed period, three sets of assays were used: (1) Architect rHTLV-I/II + HTLV Blot 2.4 (Western blot [WB]); (2) Alinity s HTLV I/II Reagent Kit + INNO-line immunoassay (LIA) HTLV I/II Score (LIA); (3) Alinity + WB. The analysed period comprised a total of 1,557,333 donations. The mean percentage of HTLV reactive donors using the Architect assay was 0.14%. With the change to the Alinity assay, that percentage dropped 2.3-fold (0.06%). The reactivity rate in the confirmatory tests (1064 samples) ranged from 13.5% to 30.2%, whereas 58.3%-85.9% of samples were non-reactive. The highest rates of positive (30.2%) and indeterminate (11.5%) results were seen using LIA. Considering all analysed samples, those with signal/cut-off ratio (S/CO) >50 were positive in confirmatory tests (positive predictive value, PPV = 100%), whereas samples with S/CO ≤6 are very unlikely to be truly positive (PPV = 0). The use of the Alinity assay reduced the frequency of false-positive results. Confirmatory tests are important to identify true HTLV infection in blood donors, because more than 58% of initially reactive individuals are confirmed as seronegative. Categorizing S/CO values is useful for assessing the likelihood of true HTLV-1/2 infection.
Sections du résumé
BACKGROUND AND OBJECTIVES
OBJECTIVE
Serological HTLV-1/2 screening is mandatory for blood donor candidates in Brazil. Our objective was to analyse HTLV test results in blood donors submitted for screening and confirmatory assays in a Brazilian blood bank.
MATERIALS AND METHODS
METHODS
Retrospective analysis (2017-2022) results of chemiluminescence immunoassays and confirmatory tests for HTLV-1/2 in reactive donors were performed. During the analysed period, three sets of assays were used: (1) Architect rHTLV-I/II + HTLV Blot 2.4 (Western blot [WB]); (2) Alinity s HTLV I/II Reagent Kit + INNO-line immunoassay (LIA) HTLV I/II Score (LIA); (3) Alinity + WB.
RESULTS
RESULTS
The analysed period comprised a total of 1,557,333 donations. The mean percentage of HTLV reactive donors using the Architect assay was 0.14%. With the change to the Alinity assay, that percentage dropped 2.3-fold (0.06%). The reactivity rate in the confirmatory tests (1064 samples) ranged from 13.5% to 30.2%, whereas 58.3%-85.9% of samples were non-reactive. The highest rates of positive (30.2%) and indeterminate (11.5%) results were seen using LIA. Considering all analysed samples, those with signal/cut-off ratio (S/CO) >50 were positive in confirmatory tests (positive predictive value, PPV = 100%), whereas samples with S/CO ≤6 are very unlikely to be truly positive (PPV = 0).
CONCLUSION
CONCLUSIONS
The use of the Alinity assay reduced the frequency of false-positive results. Confirmatory tests are important to identify true HTLV infection in blood donors, because more than 58% of initially reactive individuals are confirmed as seronegative. Categorizing S/CO values is useful for assessing the likelihood of true HTLV-1/2 infection.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Fundação HEMOMINAS
Informations de copyright
© 2023 International Society of Blood Transfusion.
Références
Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci U S A. 1980;77:7415-7419.
Gessain A, Cassar O. Epidemiological aspects and world distribution of HTLV-1 infection. Front Microbiol. 2012;3:388.
Murphy EL, Olivier C, Gessain A. Estimating the number of HTLV-2 infected persons in the world. Retrovirology. 2015;12:O5.
Barrionuevo-Cornejo C, Dueñas-Hancco D. Neoplastic hematological diseases associated with HTLV-1 infection. Semin Diagn Pathol. 2020;37:98-103.
Malpica L, Enriquez DJ, Castro DA, Peña C, Idrobo H, Fiad L, et al. Real-world data on adult T-cell leukemia/lymphoma in Latin America: a study from the Grupo de Estudio Latinoamericano de Linfoproliferativos. JCO Glob Oncol. 2021;7:1151-1166.
Yamano Y, Sato T. Clinical pathophysiology of human T-lymphotropic virus-type 1-associated myelopathy/tropical spastic paraparesis. Front Microbiol. 2012;3:389.
Yamakawa N, Yagishita N, Matsuo T, Yamauchi J, Ueno T, Inoue E, et al. Creation and validation of a bladder dysfunction symptom score for HTLV-1-associated myelopathy/tropical spastic paraparesis. Orphanet J Rare Dis. 2020;15:175.
Schierhout G, McGregor S, Gessain A, Einsiedel L, Martinello M, Kaldor J. Association between HTLV-1 infection and adverse health outcomes: a systematic review and meta-analysis of epidemiological studies. Lancet Infect Dis. 2020;20:133-143.
Caterino-de-Araujo A, Alves FA, Campos KR, Lemos MF, Moreira RC. Making the invisible visible: searching for human T-cell lymphotropic virus types 1 and 2 (HTLV-1 and HTLV-2) in Brazilian patients with viral hepatitis B and C. Mem Inst Oswaldo Cruz. 2018;113:130-134.
Ruiz-Mateos E, Ruiz-León MJ, Tarancón-Díez L, Gutiérrez C, Dronda F, Domínguez-Molina B, et al. High CD8 T cell percentage and HCV replication control are common features in HIV-1 controllers and HTLV-2-co-infected patients with a history of injection drug use. Virus Res. 2019;264:40-44.
Araujo AQ-C. Neurological aspects of HIV-1/HTLV-1 and HIV-1/HTLV-2 coinfection. Pathogens. 2020;9:250.
Rosadas C, Menezes MLB, Galvão-Castro B, Assone T, Miranda AE, Aragón MG, et al. Blocking HTLV-1/2 silent transmission in Brazil: current public health policies and proposal for additional strategies. PLoS Negl Trop Dis. 2021;15:e0009717.
Cassar O, Gessain A. Serological and molecular methods to study epidemiological aspects of human T-cell lymphotropic virus type 1 infection. In: Casoli C, editor. Human T-lymphotropic viruses methods in molecular biology. New York, NY: Humana Press; 2017. p. 3-24.
da Silva BV, Santos FLN, Gonçalves NLS, Araujo THA, Nascimento DSV, Pereira FM, et al. Performance of commercially available serological screening tests for human T-cell lymphotropic virus infection in Brazil. J Clin Microbiol. 2018;56:e00961-18.
Caterino-de-Araujo A, Barbosa-Stancioli EF, Alonso Neto JB, Aragón MG, Galvão-Castro B, Ishak R, et al. Laboratory diagnosis of human T-lymphotropic virus in Brazil: assays, flowcharts, challenges, and perspectives. Rev Soc Bras Med Trop. 2021;54:e01752021.
Brasil. Ministry of Health Ordinance N° 1,376, dated 19 November, 1993. HTLV tests and algorithm for screening blood donors.
Kiely P, Hoad VC, Wood EM. False positive viral marker results in blood donors and their unintended consequences. Vox Sang. 2018;113:530-539.
da Silva Malta MCF, Silva SMN, de Oliveira MB, Ribeiro MA, Martins ML. Decline in human T-cell lymphotropic virus seroprevalence in blood donors from Minas Gerais, Brazil over a 12-year period (2006-2017). J Med Virol. 2022;94:5535-5542.
Silva-Malta MCF, Rodrigues DOW, Chaves DG, Magalhães NNS, Ribeiro MA, Cioffi JGM, et al. Impact of COVID-19 in the attendance of blood donors and production on a Brazilian Blood Centres. Transfus Med. 2021;31:206-212.
Ji H, Chang L, Yan Y, Jiang X, Sun H, Guo F, et al. A strategy for screening and confirmation of HTLV-1/2 infections in low-endemic areas. Front Microbiol. 2020;11:1151.
Césaire R, Bera O, Maier H, Lezin A, Martial J, Ouka M, et al. Seroindeterminate patterns and seroconversions to human T-lymphotropic virus type I positivity in blood donors from Martinique, French West Indies. Transfusion. 1999;39:1145-1149.
Berini CA, Eirin ME, Pando MA, Biglione MM. Human T-cell lymphotropic virus types I and II (HTLV-I and -II) infection among seroindeterminate cases in Argentina. J Med Virol. 2007;79:69-73.
Martins ML, Santos ACS, Namen-Lopes MS, Barbosa-Stancioli EF, Utsch DG, Carneiro-Proietti ABF. Long-term serological follow-up of blood donors with an HTLV-indeterminate western blot: antibody profile of seroconverters and individuals with false reactions. J Med Virol. 2010;82:1746-1753.
Sabino EC, Zrein M, Taborda CP, Otani MM, Ribeiro-Dos-Santos G, Sáez-Alquézar A. Evaluation of the INNO-LIA HTLV I/II assay for confirmation of human T-cell leukemia virus-reactive sera in blood bank donations. J Clin Microbiol. 1999;37:1324-1328.
Campos KR, Santos FLN, Brito VS, Gonçalves NLS, Araujo THA, Galvão-Castro B, et al. Line immunoassay for confirmation and discrimination of human T-cell lymphotropic virus infections in inconclusive Western blot serum samples from Brazil. J Clin Microbiol. 2019;58:e01384-19.
Lee T-H, Chafets DM, Busch MP, Murphy EL. Quantitation of HTLV-I and II proviral load using real time quantitative PCR with SYBR Green chemistry. J Clin Virol. 2004;31:275-282.
Olindo S, Lézin A, Cabre P, Merle H, Saint-Vil M, Edimonana Kaptue M, et al. HTLV-1 proviral load in peripheral blood mononuclear cells quantified in 100 HAM/TSP patients: a marker of disease progression. J Neurol Sci. 2005;237:53-59.
Andrade RG, Ribeiro MA, Namen-Lopes MSS, Silva SMN, Basques FV, Ribas JG, et al. Evaluation of the use of real-time PCR for human T cell lymphotropic virus 1 and 2 as a confirmatory test in screening for blood donors. Rev Soc Bras Med Trop. 2010;43:111-115.
Costa EAS, Magri MC, Caterino-de-Araujo A. The best algorithm to confirm the diagnosis of HTLV-1 and HTLV-2 in at-risk individuals from São Paulo, Brazil. J Virol Methods. 2011;173:280-286.
Tosswill JHC, Taylor GP. Interpretation of low reactivity in the Abbott Architect rHTLV I/II assay. Transfus Med. 2018;28:326-330.
Lee N, Murphy J, Al-Khudairi R, Sturdy A, Mahungu T, Haque T, et al. Diagnostic accuracy of Abbott Architect Assay as a screening tool for human T-cell leukaemia virus type-1 and type-2 infection in a London teaching hospital with a large solid organ transplant centre. Transfus Med. 2022;32:256-260.
Cruz LJN, Maneschy CA, Barile KAS, Palmeira MK, Amaral CEM. Results of a sample-to-cutoff ratio using Abbott Architect rHTLV-I/II assay allow to predict detection of HTLV-1 and HTLV-2 proviral DNA by real-time PCR. Rev Inst Adolfo Lutz São Paulo. 2022;81:e37345.
Amianti C, Bandeira LM, Romeiro JS, Nakao BRO, Vavas MTM, Domingos JA, et al. HTLV infection in blood donors from Mato Grosso do Sul state: a closer look at HTLV screening in Brazilian blood banks. Sci Rep. 2023;13:14524.